藤黄酸下调蛋白C受体表达杀伤三阴性乳腺癌干细胞的作用机制  

Action mechanism by which gambogic acid down-regulates expression of protein C receptor to kill triple negative breast cancer stem cells

作　　者：李溯 王清华 达梦婷 杨蕊 陈道桢 Li Su;Wang Qinghua;Da Mengting;Yang Rui;Chen Daozhen(Department of Eugenic Genetics Institute,Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University,Wuxi 214002,Jiangsu Province,China;Eugenic Genetics Institute,Jiangnan University Maternity Hospital,Wuxi 214002,Jiangsu Province,China;Breast Disease Treatment Center,Medical College of Qinghai University,Xining 810000,Qinghai Province,China;Dean’s Office,Second People’s Hospital of Haidong City,Haidong 810600,Qinghai Province,China)

机构地区：[1]南京医科大学附属无锡妇幼保健院优生优育医学遗传研究所,江苏省无锡市214002 [2]江南大学附属妇产医院优生优育医学遗传研究所,江苏省无锡市214002 [3]青海大学附属医院乳腺疾病诊疗中心,青海省西宁市810000 [4]青海省海东市第二人民医院院长办公室,青海省海东市810600

出　　处：《中国组织工程研究》2025年第23期4888-4898,共11页Chinese Journal of Tissue Engineering Research

基　　金：青海省自然科学基金面上项目(2022-ZJ-912),项目负责人:陈道桢。

摘　　要：背景:藤黄酸对乳腺癌具有很强的细胞毒性,可有效杀伤三阴性乳腺癌干细胞,但潜在的机制尚不清楚。目的:探讨藤黄酸对三阴性乳腺癌干细胞的杀伤作用及可能的机制。方法:使用PharmMapper数据库预测藤黄酸的靶点蛋白,使用String网站构建各药物靶点蛋白互作网络关系,使用Cytoscape软件构建活性成分-作用靶点网络,通过R语言软件对潜在靶点进行KEGG信号通路富集分析。采用CCK-8法检测不同浓度藤黄酸对人乳腺癌细胞株MDA-MB-231活力的影响,筛选适宜的作用浓度。采用细胞球培养法富集MDA-MB-231细胞干细胞,经过不同浓度(0,0.5,1.0,2.0μmol/L)藤黄酸作用24 h,TUNEL荧光染色与流式细胞仪检测干细胞凋亡,qPCR与Western blot检测蛋白C受体表达,Western blot检测p-PI3K、p-AKT、Caspase-3和Cleaved Caspase-3蛋白表达;将干细胞分4组培养:空白对照组(干细胞不做任何处理)、siRNA-NC组、siRNA-蛋白C受体组和siRNA-蛋白C受体+PI3K激动剂组,培养36 h后,采用Western blot法检测p-PI3K、p-AKT、Caspase-3和Cleaved Caspase-3蛋白表达。结果与结论:(1)网络药理学发现,三阴性乳腺癌干细胞标志物蛋白C受体是藤黄酸的作用靶点之一;KEGG富集分析涉及细胞凋亡、上皮生长因子受体、RAS和PI3K-AKT信号通路等;(2)CCK-8检测结果显示,藤黄酸可抑制MDA-MB-231细胞活力,半数抑制浓度IC50值为(1.18±0.34)μmol/L,因此后续实验选择浓度0.5,1.0,2.0μmol/L;(3)TUNEL荧光染色和流式细胞术检测证实,藤黄酸以剂量依赖的方式诱导三阴性乳腺癌干细胞凋亡(P <0.05);qPCR和Western blot检测证实,藤黄酸可下调蛋白C受体mRNA和蛋白表达,下调Caspase-3、p-PI3K和p-AKT蛋白表达,上调Cleaved Caspase-3蛋白表达(P <0.05);siRNA-蛋白C受体转染实验也进一步证实,敲低三阴性乳腺癌干细胞蛋白C受体表达可提升Cleaved Caspase-3蛋白表达(P <0.05)、下调PI3K/AKT信号通路磷酸化水平(P <0.05),而应用PIBACKGROUND:Gambogic acid is highly cytotoxic to breast cancer and can effectively kill triple negative breast cancer stem cells,but the underlying mechanism is still unclear.OBJECTIVE:To investigate the lethal effect of gambogic acid on triple negative breast cancer stem cells as well as the possible mechanisms.METHODS:PharmMapper database was used to predict the target protein of gambogic acid.String website was used to construct the protein interaction network of various drug targets.Active ingredient-target network was constructed by Cytoscape software.KEGG signal pathway enrichment analysis was performed on potential targets by R language software.The effect of different concentrations of gambogic acid on the activity of human breast cancer cell line MDA-MB-231 was detected by CCK-8 assay.The appropriate concentration was screened.MDA-MB-231 stem cells were enriched by cell ball culture method and treated with gambogic acid at different concentrations(0,0.5,1.0,and 2.0μmol/L)for 24 hours.TUNEL fluorescence staining and flow cytometry were used to detect apoptosis of stem cells.qPCR and western blot assay were used to detect protein C receptor expression.The expression levels of p-PI3K,p-AKT,Caspase-3,and cleaved Caspase-3 were detected by western blot assay.Stem cells were cultured in four groups:Blank control group(stem cells were not treated),siRNA-NC group,siRNA-protein C receptor group,and siRNA-protein C receptor+PI3K agonist group.After culture for 36 hours,the expression levels of p-PI3K,p-AKT,Caspase-3,and cleaved Caspase-3 were detected by western blot assay.RESULTS AND CONCLUSION:(1)Network pharmacology exhibited that the protein C receptor,a marker of triple negative breast cancer stem cells,was one of the targets of gambogic acid.KEGG enrichment analysis involved apoptosis,epithelial growth factor receptor,RAS,and PI3K-AKT signaling pathways.(2)CCK-8 assay results showed that gambogic acid could inhibit the viability of MDA-MB-231 cells,and the median inhibitory concentration IC50 value was(1.18�

关 键 词：三阴性乳腺癌 干细胞 网络药理学 藤黄酸 分子机制 信号通路 

分 类 号：R453[医药卫生—治疗学] R319[医药卫生—临床医学] R73-36